1. Home
  2. BCG vs EVAX Comparison

BCG vs EVAX Comparison

Compare BCG & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BCG

Binah Capital Group Inc.

N/A

Current Price

$1.22

Market Cap

21.6M

Sector

N/A

ML Signal

N/A

Logo Evaxion Biotech

EVAX

Evaxion Biotech

N/A

Current Price

$2.73

Market Cap

25.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BCG
EVAX
Founded
2016
2008
Country
United States
Denmark
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.6M
25.5M
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
BCG
EVAX
Price
$1.22
$2.73
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $12.25
AVG Volume (30 Days)
8.8K
★ 124.5K
Earning Date
11-12-2026
11-19-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 112.50
N/A
EPS
★ 0.22
N/A
Revenue
★ $187,144,000.00
N/A
Revenue This Year
$3.23
N/A
Revenue Next Year
$3.75
N/A
P/E Ratio
$5.00
★ N/A
Revenue Growth
★ 10.80
N/A
52 Week Low
$0.95
$2.67
52 Week High
$3.44
$6.92

Technical Indicators

Market Signals
Indicator
BCG
EVAX
Relative Strength Index (RSI) 61.28 41.65
Support Level $0.95 N/A
Resistance Level $1.58 $3.62
Average True Range (ATR) 0.07 0.25
MACD 0.01 -0.03
Stochastic Oscillator 71.73 17.09

Price Performance

Historical Comparison
BCG
EVAX

About BCG Binah Capital Group Inc.

Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.

About EVAX Evaxion Biotech

Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.

Share on Social Networks: